Goldman Sachs
RLMD icon

Goldman Sachs’s Relmada Therapeutics RLMD Stock Holding History

Goldman Sachs’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Hold
24,300
– – ﹤0.01% 6127
2025
Q4 		$117K Buy
+24,300
New +$81.4K ﹤0.01% 6165
2021
Q3 		– Sell
-12,600
Closed -$403K – 6468
2021
Q2 		$403K Hold
12,600
– – ﹤0.01% 5341
2021
Q1 		$444K Buy
+12,600
New +$441K ﹤0.01% 5207

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs's RLMD Position: Q1 2026 in Review

Goldman Sachs increased its Relmada Therapeutics (RLMD) stake by 382% in Q1 2026, buying an estimated $2.62M and bringing the position to 699,039 shares worth $4.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Goldman Sachs first reported a position in RLMD in Q4 2019 and has held it in 18 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Goldman Sachs held 699,039 shares of Relmada Therapeutics worth $4.87M as of Q1 2026.
  • Goldman Sachs bought 554,039 Relmada Therapeutics shares in Q1 2026, an estimated $2.62M.
  • Relmada Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3717 holding.
  • Goldman Sachs first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.